Mark Bamforth is the founder and President & CEO of Arranta Bio, which was established in May 2019.

In 2015, Mr. Bamforth founded Brammer Bio, a viral vector CDMO supporting cell and gene therapy companies, which grew from 100 to 600 employees, with a team in Florida producing early clinical materials and two commercial manufacturing sites in Massachusetts. Brammer Bio was acquired by Thermo Fisher Scientific in April 2019.

In 2010, Mr. Bamforth founded Gallus BioPharmaceuticals, a CDMO supplying biopharmaceuticals, with the acquisition of a commercial facility in St. Louis from Janssen. Including the subsequent acquisition of Laureate Biopharma in Princeton, NJ, the experienced team expanded from 160 to over 400. In September 2014, Gallus was sold to DPx Holdings B.V., which later became part of Thermo Fisher Scientific.

Prior to this, Mr. Bamforth gained 22 years of experience in the UK and USA at Genzyme Corp, including running a diverse global manufacturing operation and pharmaceutical CMO business. He began his career as a petroleum engineer in the UK exploration for North Sea oil, then became a chemical engineer in the Scottish whisky industry.

Mr. Bamforth serves on the Boards of MassBio, Entrepreneurial Scotland, the Wentworth Institute of Technology, Continuus Pharmaceuticals and Avid Bioservices. He holds a Bachelor’s Degree in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.

Iain Baird is co-founder of Arranta Bio, which was established in May 2019.

Mr. Baird has worked with the founders/CEOs of 6 companies over the last 10 years starting companies developing new biological pharmaceutical products and CDMO’s providing services to the sector, including OSO BioPharmaceuticals Manufacturing, CANbridge Life Sciences, Gallus Biopharmaceuticals, and Brammer Bio.

Prior to that Mr. Baird worked for 20 years, in the pharmaceutical and chemical industries. He started work for ICI which later became Zeneca and then AstraZeneca. An engineer by discipline he initially designed and project managed the building of pharmaceutical facilities before moving into operational management running multiple production facilities in the United Kingdom. Since 2002 he has worked in the USA and was part of the leadership team that established the Avecia Oligonucleotides business as a CMO, taking a small team of researchers and growing it into an FDA approved manufacturing site with 150 employees. In 2006 Mr. Baird was one of the principles that established Avecia Vaccines in which he led the Chemistry Manufacturing and Control groups in the development of vaccines against anthrax and plague.

Since 2010 Iain has been an independent consultant assisting clients in the development of their clinical products and has been involved in filing 16 IND’s, 3 successful BLA applications and 3 successful NDA applications as well as remediating a product placed on CMC hold by the FDA. Iain has supported clients through numerous FDA, EMA and international regulatory inspections, preparing them for the inspections, supporting them during the inspections and in their successful responses.

Mr. Baird holds a BEng in mechanical and electrical engineering from Robert Gordons University.

Dr. Aaron Cowley is the Chief Scientific Officer at Arranta Bio, having been a co-founder and the Chief Technical Officer of Captozyme, which served the microbiome CDMO market for 10 years since 2009 and merged with Arranta Bio in October 2019.

He is a renowned member of the biotech community and was the recipient of the prestigious Ruth L. Kirschstein National Research Service Award for his post-doctoral work at the University of Georgia. His further work has resulted in 15 peer-reviewed journal articles.

Prior to establishing Captozyme in 2009, Dr. Cowley was a Scientist II/Preclinical Manager at OxThera, Inc. in Alachua, Florida.

He holds a Bachelor’s Degree in Biochemistry from Benedictine College, a Ph.D in Inorganic Chemistry from the University of Kansas, and an MBA from the University of Florida.

David Stevens is the Chief Operations Officer of Arranta Bio. In this role, Mr. Stevens is responsible for Arranta’s operations functions including laboratories, manufacturing, client program management and engineering.

Mr. Stevens brings over 20 years of broad international operations and commercial experience in the CRO and CDMO sectors. He was formerly the Senior Vice President & Head of AMRI’s Drug Product business unit where he had P&L responsibility for sales and operations. During his tenure, he led the division through a period of significant growth and capacity expansion. Before leading the division, Mr. Stevens held senior leadership roles at AMRI including Vice President, Sales & Marketing and General Manager of a sterile dosage form development and GMP manufacturing facility.

Prior to AMRI, Mr. Stevens held roles of increasing responsibility at Aptuit including a long-term international assignment in Italy where he led Operational Excellence and Capacity Planning for a >400 employee R&D & clinical GMP facility. He started his career with Inveresk and Charles River Laboratories.

Mr. Stevens holds an MBA in strategy, finance and marketing from the University of Edinburgh and an undergraduate degree in Business from Edinburgh.

Steve Favaloro is Chief Financial Officer of Arranta Bio. In this role, he oversees the company’s accounting, tax, treasury, financial planning, and IT functions.

He was formerly the Chief Financial Officer at Brammer Bio, with responsibility for overseeing the financial health and information systems during a period of rapid growth and the execution of a $200M capacity expansion program.

Prior to joining Brammer Bio, Mr. Favaloro held various FP&A roles at Bruker Corporation, including an assignment supporting multiple manufacturing operations in Germany and Switzerland. He began his career at Millipore Corporation, where he spent time in various accounting and FP&A roles before and after the acquisition of Millipore by Merck KGaA.

Mr. Favaloro holds a BA in Economics from Boston College, an MS, Finance, and an MBA from the Carroll School of Management at Boston College.

Lana Gladstein is the Chief Legal Officer & General Counsel for Arranta Bio. She oversees all legal matters relating to the company, operations, IP, licensing, etc.

Ms. Gladstein was previously Executive Vice President, General Counsel and Chief Legal Officer of Brammer Bio. Subsequently, through acquisitions of that entity, she served as Head of Legal for Viral Vector Services at Thermo Fisher Scientific.

Prior to joining Brammer Bio in 2017, Ms. Gladstein was a partner at the law firms of Nutter McClennen & Fish LLP and Pepper Hamilton LLP, where she represented biotechnology, pharmaceutical, and medical device companies in IP litigation, contested matters at the USPTO, IP strategy, and licensing transactions.

Ms. Gladstein received her B.A. degree in Biology from Brandeis University and her J.D. from Northeastern University School of Law.

Tom Boggiano is the Vice President of Information Technology for Arranta Bio. In this role he oversees the company’s technology needs, all information and collaboration platforms.

He was formerly the Vice President of Information Services as Brammer Bio, through acquisition he was the Head of Information Technology for Viral Vector Services at Thermo Fisher Scientific.

Prior to joining Brammer, Mr. Boggiano help various Information Technology roles at Charles River Laboratories, including global operations and head of IT for the Safety Services division. In addition to Charles River Mr. Boggiano held positions at GelTex Pharmaceuticals, Worcester Polytechnic Institute and Raytheon Co.

Mr. Boggiano holds a BS in Electrical Engineering from Worcester Polytechnic and multiple Industry specific certifications

Melanie Cerullo is the Vice President of Quality and Regulatory for Arranta Bio. In this role she is responsible for Arranta’s Quality and Regulatory functions, including Quality Assurance and Quality Control.

Ms. Cerullo has more than 23 years of experience in QA and QC in GMP manufacturing operations.  She was formerly the Vice President of CMC and Quality at Wave Life Sciences where she built the Quality organization to support early phase internal manufacture and quality oversight of CDMO’s for multiple early and late phase clinical programs.  Additionally she managed the Analytical Development and Drug Product Formulation teams developing formulations with demonstrated stability.

During her time at Wave she also took on the role of CMC leader, during which she established and managed the CMC product development program for all of Wave’s clinical portfolio.

Prior to joining Wave, Ms. Cerullo held various roles of increasing responsibility in both QA and QC for CDMO and commercial manufacturing operations.

Ms. Cerullo holds a BS in Chemistry from Rhode Island College and a MS in Quality Assurance and Regulatory Affairs from Temple University.

Shailesh Maingi is the founder and CEO of Kineticos Life Sciences, a boutique advisory focused on strategy, licensing and commercial product launch, which he established in 2007. In 2019 he founded the Kineticos Disruptor Fund, which launches and funds early stage biotech companies focused on oncology, neurodegenerative and rare diseases. The Kineticos Disruptor Fund has recently launched InceptorBio, a biotech incubator/accelerator hub. Shailesh has served on the Board of Directors of a number of biotech companies, including Gallus Biopharmaceuticals, a biologics CDMO, and Locus Biosciences, a CRISPR gene editing start-up. Additionally, Shailesh has started the non-profit, InVincible Cancer Research Fund, supporting cancer research. He also is an Adjunct Professor at the University of North Carolina at Chapel Hill. Shailesh earned a B.S. in Chemistry from UNC, Chapel Hill and an MBA from Golden Gate University.